Lakefront Biotherapeutics valuation

LKFT · Euronext Amsterdam · EUR

Compare Lakefront Biotherapeutics
€30.38Change from previous close: −1.62%Absolute change: −€0.50

Close · November 20, 2026

Valuation

The P/E ratio is 2.53. The average price target of 7 analysts is €32.61.

Data as of November 22, 2026

Lakefront Biotherapeutics compared with similar companies

Lakefront Biotherapeutics's P/E (trailing 12 months): 2.53, −83% against the median of a group of 9 similar companies (14.7).

Lakefront Biotherapeutics's metrics compared with similar companies
MetricLakefront BiotherapeuticsMedian25th–75th percentileBand
P/E (trailing 12 months)2.5314.76.16 – 38.0Low
Price/book0.613.621.52 – 8.03Low
Price/sales2.014.082.56 – 11.5Low
Gross margin67.6%87.2%58.9% – 93.2%Middle
Operating margin57.5%21.3%15.4% – 43.5%High
Net margin60.2%24.3%8.4% – 45.1%High
ROE20.1%16.6%10.5% – 27.7%Middle
Debt/equity0.000.030.02 – 0.34Low

Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.

TickerLandia analysisHow it is calculated

Companies in the group: same industry, similar size

Other metrics

Valuation multiples

Market cap
€1.99B
Enterprise value
-€238.58M
Forward P/E
-10.9
EV/EBITDA
-0.42
EV/revenue
-0.24

Profitability and growth

ROA
9.9%
ROIC
12.0%
Revenue growth (year over year)
-81.5%
Earnings growth (year over year)
-101.9%

Financial health

Total cash
€2.24B
Total debt
€6.36M
Current ratio
32.8
Quick ratio
32.6
Altman Z-Score
13.9
Piotroski F-Score
5.00

Dividends

Dividend yield
0.0%
Payout ratio
0.0%

Analysts and estimates

Average price target
€32.61
Median price target
€36.00
High price target
€44.80
Low price target
€19.00
Analysts with a price target
7
Consensus
Hold
Forward EPS
-€2.78
EPS estimate, current year
-€1.83

Shares and trading

Beta
0.01
Average volume
92.59K
Shares outstanding
65.48M
Float
23.02M
Institutional ownership
43.6%
Insider ownership
25.4%